US20050101764A1 - Process for the preparation of peptides - Google Patents
Process for the preparation of peptides Download PDFInfo
- Publication number
- US20050101764A1 US20050101764A1 US11/012,439 US1243904A US2005101764A1 US 20050101764 A1 US20050101764 A1 US 20050101764A1 US 1243904 A US1243904 A US 1243904A US 2005101764 A1 US2005101764 A1 US 2005101764A1
- Authority
- US
- United States
- Prior art keywords
- scavenger
- anion
- component
- preparation
- carboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
Definitions
- the invention relates to a new and versatile process for the preparation of compounds containing one or more amide bonds, in particular peptides, especially for processes performed in solution.
- Peptides are synthesized either in solution or on a solid support. In both approaches coupling and deprotection steps repetitively alternate and may be separated by intermittent purifications. An excess of an activated carboxylic component is preferably used in each coupling step to ensure quantitative coupling to an amino component; thus the occurrence of deletion sequences in the final product can be avoided. In solid phase peptide synthesis residual activated carboxylic component is usually removed by filtration at the end of each coupling step. In solution phase synthesis it is usually assumed that the residual activated carboxylic component is destroyed and removed during the intermittent aqueous work-up.
- Insertion peptide sequences are often encountered in solution phase synthesis as impurities of the final peptide due to incomplete removal of residual (activated) carboxylic component after a coupling step, which subsequently has coupled following deprotection.
- a scavenging step may be introduced directly after the coupling step to scavenge (inactivate) the residual activated carboxylic functions.
- Amines are usually applied as scavengers.
- polyamines as scavengers leads to scavenged compounds which may be actively extracted into a—preferably acidic—aqueous phase, depending on their polarity [e.g. Kisfaludy, L. et al.
- Bsmoc 1,1-dioxobenzo[b]thiophene-2-ylmethoxycarbonyl
- a new process has now been found for the preparation of peptides, wherein an excess of an activated carboxylic component is used to acylate an amino component, and wherein after the acylation an amine comprising a free anion or a latent anion (i.e. anion forming upon deprotection) is used as a scavenger of residual activated carboxylic functions.
- This new process allows an essentially arbitrary choice of the protecting group at the N-terminus of the activated carboxylic component, since—in contrast to the Carpino process—deprotection thereof does not necessarily take place under the same reaction conditions as the scavenging of excess of activated carboxylic functions.
- the process of this invention allows for highly efficient removal of residual activated carboxylic component without encountering the hydrophobicity problems of other prior art processes in which polyamines are used as scavengers.
- the process of the invention takes place in solution.
- the process may also be applied in solid phase peptide synthesis.
- the process of the invention is also suitable for the preparation of other compounds containing one or more amide bonds.
- an amine comprising a latent anion is used as the scavenger.
- the latent anion in the scavenging amine bears a temporary protecting group which can be selectively removed in the presence of any permanent protecting group attached to the growing peptide.
- the protecting group of the latent anion in the scavenging amine displays a lability similar to that of the temporary protecting group present at the N-terminus of the growing peptide. This allows the deprotection of the scavenger yielding the anion and the N-terminal deprotection of the growing peptide to take place in a single process step.
- the temporary protecting groups, present at the N-terminus of the growing peptide and optionally present in the scavenger are hydrogenolytically removable groups whereas the permanent protecting groups are acidolytically removable protecting groups.
- said temporary protecting groups are of the benzyl type, e.g.
- a preferred scavenger is a primary amine comprising a free anion or a latent anion, and in particular a C-terminally protected amino acid derivative. Besides carboxylate, the scavenging amine may comprise other anionic functions such as—but not limited to—sulfonate, sulfate, phosphonate, phosphate or phenolate.
- a highly preferred amino acid for use as a scavenger is ⁇ -alanine or a derivative thereof (e.g. an ester or silyl ester derivative). The most preferred scavenger is benzyl ⁇ -alaninate or a salt thereof.
- a thiol comprising a free or a latent anion may also be used as a scavenger instead of an amine comprising a free or a latent anion according to the process of this invention.
- the scavenger is preferably used in a two- to sixfold molar excess with respect to the residual active component that needs to be scavenged.
- a scavenger according to the present invention leads to hydrophilic scavenged compounds which may be actively extracted into a basic aqueous phase after the deprotection step: upon deprotection (if applicable), hydrophilicity is enhanced by the presence of both a free amino function and a free carboxylic function in the scavenged species.
- the process of this invention results in a very effective intermittent purification due to the possibility of actively extracting a hydrophilic scavenged compound.
- a possibly present excess of carboxylic component which was not activated and whose temporary protecting group was also removed during deprotection is extracted from the reaction mixture at the same time.
- the new process of this invention may conveniently be used in the preparation of oligo- and polypeptides and, more generally, in the preparation of compounds containing one or more amide bonds.
- a suitable process according to the present invention is the coupling of an excess of a carboxylic component to an amino component, wherein the carboxylic function is preactivated or activated in situ using a coupling reagent and, if desired, an additive.
- a coupling reagent and, if desired, an additive.
- residual activated carboxylic functions are scavenged by adding the scavenger to the reaction mixture.
- temporary protecting groups are removed using suitable methods known in the art, followed by removal of the scavenged compound by basic aqueous extraction.
- a possibly present excess of carboxylic component which was not activated and whose temporary protecting group was also removed during deprotection is extracted from the reaction mixture.
- amino component refers to a molecule comprising a free amino function.
- the amino component may be any amine, amino acid or oligopeptide which bears a free amino function and whose other functional groups are protected in such a manner that they do not interfere with the desired coupling reaction.
- the C-terminal function of the applied amino acid or oligopeptide may be protected as a substituted or unsubstituted amide or as an ester; examples of the latter include—but are not limited to—methyl, ethyl, t-butyl, benzyl, phenacyl, 3-(3-methyl)pentyl (Mpe), 2-(2-phenyl)propyl (Pp), 2-chlorotrityl (Clt), diphenyl(4-pyridyl)methyl (PyBzh), dicyclopropylmethyl (Dcpm), 9-fluorenylmethyl (Fm), allyl (All), 2-(trimethylsilyl)ethyl (Tmse), 4- ⁇ N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino ⁇ benzyl (Dmab) esters and enzymatically cleavable est
- t-butyl Functions of the t-butyl type or functions of similar lability are preferred for the permanent protection of other functional groups in the amino component; these include—but are not limited to—t-butyl ( t Bu) for the protection of the Asp, Glu, Ser, Thr and Tyr side chains, t-butoxycarbonyl (Boc) for the protection of the Lys and Trp side chains, trityl (Trt) for the protection of the Asn, Gln and His side chains and 2,2,5,7,8-pentamethylchromane-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) for the protection of the Arg side chain [Barany, G.
- carboxylic component refers to a molecule comprising a free carboxylic function.
- the carboxylic component may be any carboxylic acid, amino acid or oligopeptide which bears a free carboxylic function and whose other functional groups are protected in such a manner that they do not interfere with the desired coupling reaction.
- the amino group of the applied amino acid or oligopeptide is temporarily protected by a benzyloxycarbonyl (Z) function; other examples include—but are not limited to—the Boc, Trt, fluoren-9-ylmethoxycarbonyl (Fmoc), 2-(methylsulfonyl)ethoxycarbonyl (Msc), allyloxycarbonyl (Alloc) functions, functions of the arylsulfonyl type, such as ortho-nitrobenzenesulfonyl (o-NBS) and enzymatically cleavable functions [Geiger, R. and König, W. (1981) in: ‘ The Peptides’ , vol. 3 (Gross, E.
- the carboxylic component may be preactivated as an active ester, preferably an N-hydroxysuccinimide, benzotriazol-1-yl, pentafluorophenyl or 4-nitrophenyl ester, a halide, an N-carboxyanhydride or as a symmetric anhydride.
- an active ester preferably an N-hydroxysuccinimide, benzotriazol-1-yl, pentafluorophenyl or 4-nitrophenyl ester, a halide, an N-carboxyanhydride or as a symmetric anhydride.
- the carboxylic component may be activated in situ as a mixed anhydride or using a coupling reagent, such as a carbodiimide, preferably N,N′-dicyclohexylcarbodiimide (DCC) or 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), a uronium or a phosphonium salt in the possible presence of a coupling additive, preferably N-hydroxysuccinimide (HONSu), 1-hydroxybenzotriazole (HOBt), 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt), 1-hydroxy-7-azabenzotriazole (HOAt) or 6-chloro-1-hydroxybenzotriazole (Cl-HOBt) and if required in the presence of a tertiary amine [‘ The Peptides’ , vol. 1 (1979) (Gross,
- the temporary protecting group may be removed according to methods known in the art (vide supra).
- the Z function may be removed by hydrogenolysis using (standard) procedures that apply, e.g. hydrogen gas or formiate as a hydrogen donor. During this proces all benzyl-type protecting groups are removed and protecting groups of the t-butyl type or functions of similar lability are maintained. The latter may be removed by acidolysis according to the methods known in the art.
- basic aqueous extractions are preferably performed using aqueous solutions of sodium hydrogencarbonate or sodium carbonate, if desired in the presence of sodium chloride or potassium nitrate.
- active aqueous extraction refers to an extraction in which either an amino component is extracted under acidic conditions in the protonated form (ammonium) or a carboxylic component is extracted under basic conditions in the deprotonated form (carboxylate).
- the organic layer containing the protected dipeptide Z-Asp(O t Bu)-Phe-O t Bu was subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 5% Na 2 CO 3 /10% NaCl was added and the resulting suspension was filtered. The residue was washed with a mixture of ethyl acetate and dichloromethane, and the combined organic filtrates were extracted with 5% Na 2 CO 3 /10% NaCl, 30% NaCl and water. The organic layer was evaporated to dryness to give the desired dipeptide in quantitative yield.
- the organic layer containing Z-Phe-NH—(CH 2 ) 7 —CH 3 was diluted with 1-methyl-2-pyrrolidinone and subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 30% NaCl was added and the resulting suspension was filtered. The residue was washed with ethyl acetate, and the combined organic filtrates were extracted with 5% Na 2 CO 3 /10% NaCl and 30% NaCl.
- the organic layer containing Z-Leu-Phe-NH—(CH 2 ) 7 —CH 3 was diluted with 1-methyl-2-pyrrolidinone and subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 5% Na 2 CO 3 /10% NaCl was added and the resulting suspension was filtered at 45° C. The residue was washed with ethyl acetate, and the combined organic filtrates were extracted with 5% Na 2 CO 3 10% NaCl, 30% NaCl and water. The organic layer was evaporated to dryness to give the desired product in 85% yield.
Abstract
Description
- The invention relates to a new and versatile process for the preparation of compounds containing one or more amide bonds, in particular peptides, especially for processes performed in solution.
- Peptides are synthesized either in solution or on a solid support. In both approaches coupling and deprotection steps repetitively alternate and may be separated by intermittent purifications. An excess of an activated carboxylic component is preferably used in each coupling step to ensure quantitative coupling to an amino component; thus the occurrence of deletion sequences in the final product can be avoided. In solid phase peptide synthesis residual activated carboxylic component is usually removed by filtration at the end of each coupling step. In solution phase synthesis it is usually assumed that the residual activated carboxylic component is destroyed and removed during the intermittent aqueous work-up. Insertion peptide sequences, however, are often encountered in solution phase synthesis as impurities of the final peptide due to incomplete removal of residual (activated) carboxylic component after a coupling step, which subsequently has coupled following deprotection. In order to avoid the occurrence of said side-reactions a scavenging step may be introduced directly after the coupling step to scavenge (inactivate) the residual activated carboxylic functions. Amines are usually applied as scavengers. The use of polyamines as scavengers leads to scavenged compounds which may be actively extracted into a—preferably acidic—aqueous phase, depending on their polarity [e.g. Kisfaludy, L. et al. (1974) Tetrahedron Lett. 19, 1785-1786]. This extraction is usually performed before the deprotection step to avoid loss of the growing peptide into the aqueous phase. However, this procedure has in numerous cases been found to result in incomplete intermittent purification due to the hydrophobicity of the scavenged compound: the intrinsic hydrophobicity of the amino acyl part of the carboxylic component is enhanced by the still present amino-protecting group. Aqueous extraction is thus not completely effective. Recently, Carpino, L. A. et al. [(1999) J. Org. Chem. 64, 4324-4338] reported an improvement of the scavenging method. In addition to the use of a polyamine as a scavenger the amino-protecting group 1,1-dioxobenzo[b]thiophene-2-ylmethoxycarbonyl (Bsmoc) was applied in the process. The Bsmoc function has very high lability towards base. As a result thereof, residual activated carboxylic functions are scavenged and Bsmoc functions are removed in one and the same step using a polyamine.
- A new process has now been found for the preparation of peptides, wherein an excess of an activated carboxylic component is used to acylate an amino component, and wherein after the acylation an amine comprising a free anion or a latent anion (i.e. anion forming upon deprotection) is used as a scavenger of residual activated carboxylic functions. This new process allows an essentially arbitrary choice of the protecting group at the N-terminus of the activated carboxylic component, since—in contrast to the Carpino process—deprotection thereof does not necessarily take place under the same reaction conditions as the scavenging of excess of activated carboxylic functions. Furthermore, the process of this invention allows for highly efficient removal of residual activated carboxylic component without encountering the hydrophobicity problems of other prior art processes in which polyamines are used as scavengers. Preferably, the process of the invention takes place in solution. However, the process may also be applied in solid phase peptide synthesis. The process of the invention is also suitable for the preparation of other compounds containing one or more amide bonds. In a preferred embodiment, an amine comprising a latent anion is used as the scavenger. Preferably, the latent anion in the scavenging amine bears a temporary protecting group which can be selectively removed in the presence of any permanent protecting group attached to the growing peptide. In a particularly preferred embodiment the protecting group of the latent anion in the scavenging amine displays a lability similar to that of the temporary protecting group present at the N-terminus of the growing peptide. This allows the deprotection of the scavenger yielding the anion and the N-terminal deprotection of the growing peptide to take place in a single process step. Especially preferred is the process of the invention wherein the temporary protecting groups, present at the N-terminus of the growing peptide and optionally present in the scavenger, are hydrogenolytically removable groups whereas the permanent protecting groups are acidolytically removable protecting groups. Preferably, said temporary protecting groups are of the benzyl type, e.g. (substituted) benzyl and benzyloxycarbonyl groups. A preferred scavenger is a primary amine comprising a free anion or a latent anion, and in particular a C-terminally protected amino acid derivative. Besides carboxylate, the scavenging amine may comprise other anionic functions such as—but not limited to—sulfonate, sulfate, phosphonate, phosphate or phenolate. A highly preferred amino acid for use as a scavenger is β-alanine or a derivative thereof (e.g. an ester or silyl ester derivative). The most preferred scavenger is benzyl β-alaninate or a salt thereof.
- A thiol comprising a free or a latent anion may also be used as a scavenger instead of an amine comprising a free or a latent anion according to the process of this invention.
- The scavenger is preferably used in a two- to sixfold molar excess with respect to the residual active component that needs to be scavenged.
- The use of a scavenger according to the present invention leads to hydrophilic scavenged compounds which may be actively extracted into a basic aqueous phase after the deprotection step: upon deprotection (if applicable), hydrophilicity is enhanced by the presence of both a free amino function and a free carboxylic function in the scavenged species. Thus, the process of this invention results in a very effective intermittent purification due to the possibility of actively extracting a hydrophilic scavenged compound. In addition, a possibly present excess of carboxylic component which was not activated and whose temporary protecting group was also removed during deprotection, is extracted from the reaction mixture at the same time. The new process of this invention may conveniently be used in the preparation of oligo- and polypeptides and, more generally, in the preparation of compounds containing one or more amide bonds.
- A suitable process according to the present invention is the coupling of an excess of a carboxylic component to an amino component, wherein the carboxylic function is preactivated or activated in situ using a coupling reagent and, if desired, an additive. Following the coupling step, residual activated carboxylic functions are scavenged by adding the scavenger to the reaction mixture. Subsequently, temporary protecting groups are removed using suitable methods known in the art, followed by removal of the scavenged compound by basic aqueous extraction. At the same time, a possibly present excess of carboxylic component which was not activated and whose temporary protecting group was also removed during deprotection, is extracted from the reaction mixture.
- The term amino component refers to a molecule comprising a free amino function. In particular, the amino component may be any amine, amino acid or oligopeptide which bears a free amino function and whose other functional groups are protected in such a manner that they do not interfere with the desired coupling reaction. The C-terminal function of the applied amino acid or oligopeptide may be protected as a substituted or unsubstituted amide or as an ester; examples of the latter include—but are not limited to—methyl, ethyl, t-butyl, benzyl, phenacyl, 3-(3-methyl)pentyl (Mpe), 2-(2-phenyl)propyl (Pp), 2-chlorotrityl (Clt), diphenyl(4-pyridyl)methyl (PyBzh), dicyclopropylmethyl (Dcpm), 9-fluorenylmethyl (Fm), allyl (All), 2-(trimethylsilyl)ethyl (Tmse), 4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino}benzyl (Dmab) esters and enzymatically cleavable esters [Roeske, R. W. (1981) in: ‘The Peptides’, vol. 3 (Gross, E. and Meienhofer, J., eds.) Academic Press, New York, pp. 101-136; for Mpe: Karlström, A. and Undén, A. (1996) Tetrahedron Lett. 37, 4343-4246; for Pp: Yue, C. et al. (1993) Tetrahedron Lett. 34, 323-326; for Clt: Athanassopoulos, P. et al. (1995) Tetrahedron Lett. 36, 5645-5648; for PyBzh: Mergler, M. et al. (2001) P154, 2nd International Peptide Symposium & 17th American Peptide Symposium; for Dcpm: Carpino, L. A. et al. (1995) J. Org. Chem. 60, 7718-7719; for Fm: Al-Obeidi, F. et al. (1990) Int. J. Peptide Protein Res. 35, 215-218; for All: Kunz, H. et al. (1985) Int. J. Peptide Protein Res. 26, 493-497; for Tmse: Sieber, P. (1977) Helv. Chim. Acta 60, 2711-2716; for Dmab: Chan, W. C. et al. (1995) J. Chem. Soc., Chem. Commun., 2209-2210]. Functions of the t-butyl type or functions of similar lability are preferred for the permanent protection of other functional groups in the amino component; these include—but are not limited to—t-butyl (tBu) for the protection of the Asp, Glu, Ser, Thr and Tyr side chains, t-butoxycarbonyl (Boc) for the protection of the Lys and Trp side chains, trityl (Trt) for the protection of the Asn, Gln and His side chains and 2,2,5,7,8-pentamethylchromane-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) for the protection of the Arg side chain [Barany, G. and Merrifield, R. B. (1980) in: ‘The Peptides’, vol. 2 (Gross, E. and Meienhofer, J., eds.) Academic Press, New York, pp. 1-284; for Trp(Boc): Franzén, H. et al. (1984) J. Chem. Soc., Chem. Commun., 1699-1700; for Asn(Trt) and Gln(Trt): Sieber, P. and Riniker, B. (1991) Tetrahedron Lett. 32, 739-742; for His(Trt): Sieber, P. and Riniker, B. (1987) Tetrahedron Lett. 28, 6031-6034; for Pmc: Ramage, R. and Green, J. (1987) Tetrahedron Lett. 28, 2287-2290; for Pbf: Carpino, L. A. et al. (1993) Tetrahedron Lett. 34, 7829-7832].
- The term carboxylic component refers to a molecule comprising a free carboxylic function. In particular, the carboxylic component may be any carboxylic acid, amino acid or oligopeptide which bears a free carboxylic function and whose other functional groups are protected in such a manner that they do not interfere with the desired coupling reaction. In a preferred embodiment, the amino group of the applied amino acid or oligopeptide is temporarily protected by a benzyloxycarbonyl (Z) function; other examples include—but are not limited to—the Boc, Trt, fluoren-9-ylmethoxycarbonyl (Fmoc), 2-(methylsulfonyl)ethoxycarbonyl (Msc), allyloxycarbonyl (Alloc) functions, functions of the arylsulfonyl type, such as ortho-nitrobenzenesulfonyl (o-NBS) and enzymatically cleavable functions [Geiger, R. and König, W. (1981) in: ‘The Peptides’, vol. 3 (Gross, E. and Meienhofer, J., eds.) Academic Press, New York, pp. 1-99; for Alloc: Kunz, H. and Unverzagt, C. (1984) Angew. Chem. 96, 426-427; for arylsulfonyl: Fukuyama, T. et al. (1997) Tetrahedron Lett. 38, 5831-5834]. Functions of the t-butyl type or functions of similar lability are preferred for the permanent protection of other functional groups in the carboxylic component as described above for the amino component. The carboxylic component may be preactivated as an active ester, preferably an N-hydroxysuccinimide, benzotriazol-1-yl, pentafluorophenyl or 4-nitrophenyl ester, a halide, an N-carboxyanhydride or as a symmetric anhydride. Alternatively, the carboxylic component may be activated in situ as a mixed anhydride or using a coupling reagent, such as a carbodiimide, preferably N,N′-dicyclohexylcarbodiimide (DCC) or 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), a uronium or a phosphonium salt in the possible presence of a coupling additive, preferably N-hydroxysuccinimide (HONSu), 1-hydroxybenzotriazole (HOBt), 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt), 1-hydroxy-7-azabenzotriazole (HOAt) or 6-chloro-1-hydroxybenzotriazole (Cl-HOBt) and if required in the presence of a tertiary amine [‘The Peptides’, vol. 1 (1979) (Gross, E. and Meienhofer, J., eds.) Academic Press, New York; Li, P. and Xu, J.-C. (2000) Chin. J. Chem. 18, 456-466].
- The temporary protecting group may be removed according to methods known in the art (vide supra). The Z function may be removed by hydrogenolysis using (standard) procedures that apply, e.g. hydrogen gas or formiate as a hydrogen donor. During this proces all benzyl-type protecting groups are removed and protecting groups of the t-butyl type or functions of similar lability are maintained. The latter may be removed by acidolysis according to the methods known in the art.
- A person skilled in the art will understand what is meant with the term basic aqueous extraction However, basic aqueous extractions are preferably performed using aqueous solutions of sodium hydrogencarbonate or sodium carbonate, if desired in the presence of sodium chloride or potassium nitrate. The term active aqueous extraction refers to an extraction in which either an amino component is extracted under acidic conditions in the protonated form (ammonium) or a carboxylic component is extracted under basic conditions in the deprotonated form (carboxylate).
- The invention is further illustrated by the following examples, which are not to be interpreted as a limitation of this invention.
- To a stirred suspension of 5.52 g of H-Phe-OtBu.HCl in a mixture of ethyl acetate and dichloromethane at 20° C., were added 7.76 g of Z-Asp(OtBu)-OH, 3.24 g of 1-hydroxybenzotriazole, 4.20 g of 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 4.62 ml of 4-methylmorpholine. After stirring the resulting solution until completion of the reaction, 1.21 ml of 4-methylmorpholine and 3.51 g of benzyl β-alaninate p-toluenesulfonate salt were added. The mixture was stirred for another 30 minutes and was extracted with 5% Na2CO3/10% NaCl, 5% KHSO4/10% NaCl and 5% Na2CO3/10% NaCl.
- The organic layer containing the protected dipeptide Z-Asp(OtBu)-Phe-OtBu was subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 5% Na2CO3/10% NaCl was added and the resulting suspension was filtered. The residue was washed with a mixture of ethyl acetate and dichloromethane, and the combined organic filtrates were extracted with 5% Na2CO3/10% NaCl, 30% NaCl and water. The organic layer was evaporated to dryness to give the desired dipeptide in quantitative yield. Purity: 98.4% by reversed phase HPLC (24 to 68% acetonitrile in 0.1% trifluoroacetic acid in 29 minutes at 220 nm, 2.0 ml/min, 5 micron C18 column). Identity: m/z 393.4 [M+H] + by electrospray MS; 1H NMR (CDCl3) Δ 1.41 (s, 9H), 1.46 (s, 9H), 1.63 (bs, 2H), 2.39 (dd, 1H), 2.79 (dd, 1H), 3.39 (d, 2H), 3.65 (m, 1H), 4.72 (m, 1H), 7.17-7.32 (m, 5H), 7.81 (d, 1H).
- To a stirred solution of 2.12 ml of n-octylamine in ethyl acetate at 20° C., were added 4.61 g of Z-Phe-OH, 2.08 g of 1-hydroxybenzotriazole, 2.71 g of 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1.55 ml of 4-methylmorpholine. After stirring the resulting suspension until completion of the reaction, 0.78 ml of 4-methylmorpholine and 2.26 g of benzyl β-alaninate p-toluenesulfonate salt were added. The mixture was stirred for another 30 minutes and was extracted with 5% Na2CO3/10% NaCl, 5% KHSO4/10% NaCl and 5% Na2CO3/10% NaCl.
- The organic layer containing Z-Phe-NH—(CH2)7—CH3 was diluted with 1-methyl-2-pyrrolidinone and subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 30% NaCl was added and the resulting suspension was filtered. The residue was washed with ethyl acetate, and the combined organic filtrates were extracted with 5% Na2CO3/10% NaCl and 30% NaCl.
- To the organic layer containing H-Phe-NH—(CH2)7—CH3 at 20° C., were added 4.09 g of Z-Leu-OH, 2.08 g of 1-hydroxybenzotriazole, 2.71 g of 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.55 ml of 4-methylmorpholine and 1-methyl-2-pyrrolidinone. After stirring the resulting suspension until completion of the reaction, 0.78 ml of 4-methylmorpholine and 2.26 g of benzyl β-alaninate p-toluenesulfonate salt were added. The mixture was stirred for another 30 minutes and was extracted with 30% NaCl, 5% Na2CO3/10% NaCl, 5% KHSO4/10% NaCl and 5% Na2CO3/10% NaCl.
- The organic layer containing Z-Leu-Phe-NH—(CH2)7—CH3 was diluted with 1-methyl-2-pyrrolidinone and subjected to catalytic hydrogenolysis in the presence of palladium on charcoal. Upon completion of the reaction, 5% Na2CO3/10% NaCl was added and the resulting suspension was filtered at 45° C. The residue was washed with ethyl acetate, and the combined organic filtrates were extracted with 5% Na2CO310% NaCl, 30% NaCl and water. The organic layer was evaporated to dryness to give the desired product in 85% yield. Purity: 99.3% by reversed phase HPLC (24 to 68% acetonitrile in 0.1% trifluoroacetic acid in 29 minutes at 220 nm, 2.0 ml/min, 5 micron C18 column). Identity: m/z 390.4 [M+H]+, 412.4 [M+Na]+, 388.2 [M−H]−, 434.2 [M+HCOO]− by electrospray MS; 1H NMR (CDCl3) 66 0.89 (m, 9H), 1.12-1.39 (m, 14H), 1.50-1.60 (m, 3H), 3.01-3.22 (m, 4H), 3.35 (dd, 1H), 4.53 (dd, 1H), 5.90 (t, 1H), 7.19-7.32 (m, 5H), 7.83 (d, 1H).
- The purity and identification of the obtained products demonstrate that the excesses of (activated) carboxylic component have been removed completely and no insertion peptide sequences have been formed using the process of this invention.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/012,439 US20050101764A1 (en) | 2001-07-19 | 2004-12-14 | Process for the preparation of peptides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01202751 | 2001-07-19 | ||
EP01202751.2 | 2001-07-19 | ||
US10/199,785 US6864357B2 (en) | 2001-07-19 | 2002-07-19 | Process for the preparation of peptides |
US11/012,439 US20050101764A1 (en) | 2001-07-19 | 2004-12-14 | Process for the preparation of peptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/199,785 Division US6864357B2 (en) | 2001-07-19 | 2002-07-19 | Process for the preparation of peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050101764A1 true US20050101764A1 (en) | 2005-05-12 |
Family
ID=8180655
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/199,785 Expired - Lifetime US6864357B2 (en) | 2001-07-19 | 2002-07-19 | Process for the preparation of peptides |
US11/012,439 Abandoned US20050101764A1 (en) | 2001-07-19 | 2004-12-14 | Process for the preparation of peptides |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/199,785 Expired - Lifetime US6864357B2 (en) | 2001-07-19 | 2002-07-19 | Process for the preparation of peptides |
Country Status (25)
Country | Link |
---|---|
US (2) | US6864357B2 (en) |
EP (1) | EP1277761B1 (en) |
JP (1) | JP3579038B2 (en) |
KR (1) | KR100869520B1 (en) |
CN (1) | CN1254482C (en) |
AR (1) | AR035258A1 (en) |
AT (1) | ATE531724T1 (en) |
AU (1) | AU2002300166C1 (en) |
BR (1) | BRPI0202779B1 (en) |
CA (1) | CA2394216C (en) |
DK (1) | DK1277761T3 (en) |
EC (1) | ECSP024292A (en) |
ES (1) | ES2374389T3 (en) |
HK (1) | HK1050905A1 (en) |
HR (1) | HRP20020608A2 (en) |
HU (1) | HUP0202370A2 (en) |
IL (1) | IL150600A (en) |
MX (1) | MXPA02006997A (en) |
NO (1) | NO326377B1 (en) |
PE (1) | PE20030215A1 (en) |
PL (1) | PL355126A1 (en) |
RU (1) | RU2242457C2 (en) |
SG (1) | SG120874A1 (en) |
TW (1) | TWI243826B (en) |
ZA (1) | ZA200205408B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090093016A1 (en) * | 2006-01-17 | 2009-04-09 | N.V. Organon | Selective Enzymatic Hydrolysis of C-Terminal Tert-Butyl Esters of Peptides |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL150601A (en) * | 2001-07-19 | 2010-06-30 | Organon Nv | Process for rapid solution synthesis of peptides using an excess of activated carboxylic component and scavenging the residual activated carboxylic component |
US7393277B2 (en) * | 2003-08-25 | 2008-07-01 | Igt | Horseshoe payline system and games using that system |
EP1790656A1 (en) * | 2005-11-25 | 2007-05-30 | Nanokem S.A. | Solution-phase synthesis of leuprolide |
JP4684124B2 (en) * | 2006-02-16 | 2011-05-18 | 富士通株式会社 | Mobile station apparatus and transmission power control method in the same |
EP1995254B1 (en) | 2006-03-01 | 2019-04-03 | Kaneka Corporation | Method of producing peptides |
US7601062B2 (en) * | 2006-11-06 | 2009-10-13 | Igt | Gaming device and method including moving paylines |
US8124372B2 (en) * | 2007-06-25 | 2012-02-28 | N.V. Organon | Selective enzymatic amidation of C-terminal esters or acids of peptides |
US9127038B2 (en) | 2011-08-04 | 2015-09-08 | Merck Sharp & Dohme Corp. | Kisspeptide-pentasaccharide conjugates |
US9177447B2 (en) | 2012-09-25 | 2015-11-03 | Igt | Gaming system and method for providing a symbol matrix with a moveable symbol display window |
EP2907809B1 (en) * | 2014-02-14 | 2018-08-22 | Corden Pharma International GmbH | Base-free process for the preparation of ketone intermediates usable for manufacture of nebivolol |
CN115362144A (en) * | 2020-03-27 | 2022-11-18 | 株式会社钟化 | Process for producing amide bond-containing compound |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
US6121488A (en) * | 1997-09-24 | 2000-09-19 | Warner-Lambert Company | Quenching reagents for solution phase synthesis |
US6506701B1 (en) * | 1996-05-03 | 2003-01-14 | Warner-Lambert Company | Rapid purification by polymer supported quench |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221754A (en) * | 1989-06-09 | 1993-06-22 | Research Corporation Technologies, Inc. | Reagents for rapid peptide synthesis |
US5101059A (en) * | 1989-12-05 | 1992-03-31 | Research Corporation Technologies, Inc. | Amino acid protecting groups |
US5516892A (en) * | 1992-12-28 | 1996-05-14 | Indiana University Foundation | Polymer-bound mixed carboxylic anhdrides as a stable form of activated carboxylic acids |
US6310180B1 (en) * | 1993-06-21 | 2001-10-30 | Vanderbilt University | Method for synthesis of proteins |
US5849954A (en) * | 1996-01-18 | 1998-12-15 | Research Corporation Technologies, Inc. | Method of peptide synthesis |
JPH11217397A (en) * | 1997-11-27 | 1999-08-10 | Saburo Aimoto | Production of peptide thiol ester |
FR2780061B1 (en) * | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES |
AU6951400A (en) * | 1999-05-06 | 2000-12-12 | Human Genome Sciences, Inc. | Fibroblast growth factor 13 |
CA2373816A1 (en) * | 1999-05-26 | 2000-11-30 | Abbott Laboratories | Minimal isolation peptide synthesis process using ion-exchange resins as scavenging agents |
US20020127219A1 (en) * | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
AU2001277950A1 (en) * | 2000-07-19 | 2002-01-30 | Pharmacia And Upjohn Company Llc | Substrates and assays for beta-secretase activity |
-
2002
- 2002-07-04 IL IL15060002A patent/IL150600A/en unknown
- 2002-07-04 TW TW091114833A patent/TWI243826B/en active
- 2002-07-05 ZA ZA200205408A patent/ZA200205408B/en unknown
- 2002-07-05 JP JP2002197549A patent/JP3579038B2/en not_active Expired - Lifetime
- 2002-07-15 DK DK02077875.9T patent/DK1277761T3/en active
- 2002-07-15 SG SG200204299A patent/SG120874A1/en unknown
- 2002-07-15 EP EP02077875A patent/EP1277761B1/en not_active Expired - Lifetime
- 2002-07-15 AT AT02077875T patent/ATE531724T1/en active
- 2002-07-15 ES ES02077875T patent/ES2374389T3/en not_active Expired - Lifetime
- 2002-07-17 MX MXPA02006997A patent/MXPA02006997A/en active IP Right Grant
- 2002-07-18 CN CNB021261903A patent/CN1254482C/en not_active Expired - Lifetime
- 2002-07-18 HU HU0202370A patent/HUP0202370A2/en unknown
- 2002-07-18 KR KR1020020041897A patent/KR100869520B1/en not_active IP Right Cessation
- 2002-07-18 AR ARP020102686A patent/AR035258A1/en active IP Right Grant
- 2002-07-18 NO NO20023445A patent/NO326377B1/en not_active IP Right Cessation
- 2002-07-18 CA CA002394216A patent/CA2394216C/en not_active Expired - Lifetime
- 2002-07-18 AU AU2002300166A patent/AU2002300166C1/en not_active Expired
- 2002-07-18 RU RU2002119631/04A patent/RU2242457C2/en not_active IP Right Cessation
- 2002-07-18 BR BRPI0202779A patent/BRPI0202779B1/en active IP Right Grant
- 2002-07-18 PE PE2002000640A patent/PE20030215A1/en not_active Application Discontinuation
- 2002-07-19 HR HR20020608A patent/HRP20020608A2/en not_active Application Discontinuation
- 2002-07-19 EC EC2002004292A patent/ECSP024292A/en unknown
- 2002-07-19 US US10/199,785 patent/US6864357B2/en not_active Expired - Lifetime
- 2002-07-19 PL PL02355126A patent/PL355126A1/en not_active IP Right Cessation
-
2003
- 2003-04-29 HK HK03103038.5A patent/HK1050905A1/en not_active IP Right Cessation
-
2004
- 2004-12-14 US US11/012,439 patent/US20050101764A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
US6506701B1 (en) * | 1996-05-03 | 2003-01-14 | Warner-Lambert Company | Rapid purification by polymer supported quench |
US6121488A (en) * | 1997-09-24 | 2000-09-19 | Warner-Lambert Company | Quenching reagents for solution phase synthesis |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090093016A1 (en) * | 2006-01-17 | 2009-04-09 | N.V. Organon | Selective Enzymatic Hydrolysis of C-Terminal Tert-Butyl Esters of Peptides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1291356B1 (en) | Process for rapid solution synthesis of peptides | |
US6255285B1 (en) | Phenethylamine derivatives | |
US6864357B2 (en) | Process for the preparation of peptides | |
NO164245B (en) | PROCEDURE FOR PREPARING THE PEPTID H-ARG-X-Z-Y-TYR-R. | |
AU2002300066B2 (en) | Process for Rapid Solution Synthesis of Peptides | |
JPH0641188A (en) | Method for synthesizing peptide, and new synthetic intermediate | |
NZ520268A (en) | Process for the preparation of peptides | |
JPH0380147B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AKZO NOBEL N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EGGEN, IVO FRANCI;TEN KORTENAAR, PAULUS;BERNARDUS, WILHELMUS;REEL/FRAME:016100/0004 Effective date: 20020628 |
|
AS | Assignment |
Owner name: AKZO NOBEL N.V., NETHERLANDS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE SECOND INVENTOR PREVIOUSLY RECORDED AT REEL 016100 FRAME 0004;ASSIGNORS:EGGEN, IVO FRANCI;TEN KORTENAAR, PAULUS, BERNARDUS, WILHELMUS;REEL/FRAME:017218/0267 Effective date: 20020628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |